46 results on '"Lorusso, Domenica"'
Search Results
2. PO007LBA/#1550 Efficacy and safety of trastuzumab deruxtecan in patients with HER2-expressing solid tumors: results from the cervical, endometrial, and ovarian cancer cohorts of the destiny-PanTumor02 study
3. TP019/#1387 Rosella (GOG-3073, ENGOT-OV72/MITO): a phase 3 study of relacorilant + nab paclitaxel vs. nab-paclitaxel in platinum-resistant ovarian cancer
4. #1121 KEYNOTE-826: final overall survival results from a randomized, double-blind, phase 3 study of pembrolizumab + chemotherapy vs placebo + chemotherapy for first-line treatment of persistent, recurrent, or metastatic cervical cancer
5. #226 Exploring the association between different mismatch repair deficient phenotypes and prognostic factors in endometrial cancer: a descriptive analysis
6. #219 Determinants of treatment decision-making regarding maintenance therapy in advanced epithelial ovarian cancer: a European delphi study to find consensus
7. #765 Efficacy of maintenance with PARPi in advanced ovarian cancer according to the type of BRCA mutation
8. #818 Genetic implications of a comprehensive cancer genome profiling programme in a monoinstitutional study: focus on gynecological cancers
9. #881 The NUVOLA TRIAL: neoadjuvant chemoteraphy in unresectable ovarian cancer with olaparib and weekly carboplatin plus paclitaxel. A phase II open-label multi-centre study
10. #709 The effects of niraparib dose reduction on long-term outcomes in ovarian cancer patients: a large retrospective, observational study
11. #823 Comprehensive characterization of naïve treatment samples of high grade serous ovarian cancer addressed to neoadjuvant chemotherapy: a hypothesis-generating study on biomarkers of response to platinum-based chemotherapy
12. #205 ROSELLA (GOG-3073, ENGOT-Ov72/MITO): a phase 3 study of relacorilant + nab-paclitaxel vs. nab-paclitaxel in advanced, platinum-resistant ovarian cancer
13. #1056 Mirvetuximab soravtansine demonstrates efficacy over investigator’s choice chemotherapy regardless of prior PARPi exposure in phase III MIRASOL trial
14. #67 Pembrolizumab + chemotherapy for first-line treatment of patients with persistent, recurrent, or metastatic cervical cancer: bevacizumab subgroup analysis based on protocol-specified final overall survival results of KEYNOTE-826
15. #763 Impact of metformin on the efficacy of maintenance with parpi in patients with newly diagnosed ovarian cancer
16. #528 Efficacy of subsequent chemotherapy followed by PARP inhibitor maintenance in patients with advanced ovarian cancer in the phase III PAOLA-1/ENGOT-Ov25 trial
17. #1015 Mirvetuximab soravtansine demonstrates longer overall survival and progression-free survival by prior lines of therapy vs chemotherapy in platinum-resistant ovarian cancer and high folate receptor alpha expression in the MIRASOL trial
18. #512 Real-World utilisation and clinical outcomes of patients with BRCA-mutated advanced ovarian cancer treated with olaparib in the first-line maintenance setting: 2-year clinical outcomes of the pan-European OVAL-1 study
19. EP064/#192 Potential mechanism for ocular adverse events observed with tisotumab vedotin
20. TP017/#1455 A phase 2 umbrella study of retifanlimab (INCMGA00012) alone or in combination with other therapies in patients with advanced or metastatic endometrial cancer (POD1UM-204)
21. O018/#482 Updated safety of lenvatinib + pembrolizumab vs treatment of physician’s choice in patients with advanced endometrial cancer: study 309/keynote-775
22. TP004/#1457 Trial in progress of engot-CX8/GOG-3024/innovaTV 205: addition of a new cohort using first-line tisotumab vedotin + pembrolizumab + carboplatin ± bevacizumab in recurrent/metastatic cervical cancer
23. 16/#430 Phase 2 results of relacorilant + nab-paclitaxel in patients with recurrent, platinum-resistant ovarian cancer with and without prior bevacizumab
24. TP033/#1441 MITO 25.1: a randomized, molecular driven phase II trial of carboplatin-paclitaxel-bevacizumab vs carboplatin-paclitaxel-bevacizumab-rucaparib vs carboplatin-paclitaxel-rucaparib, selected according to HRD status, in patients with advanced ovarian cancer
25. O003/#557 Overall survival results from ARIEL3: a phase 3 randomized, double-blind study of rucaparib vs placebo following response to platinum-based chemotherapy for recurrent ovarian carcinoma
26. TP034/#1534 Randomized phase III trial on niraparib-TSR-042 (Dostarlimab) versus physician’s choice chemotherapy in recurrent ovarian, fallopian tube, primary peritoneal cancer platinum resistant patients: nitche trial(MITO 33)
27. O028/#376 Clinical benefit of mirvetuximab soravtansine in ovarian cancer patients with high folate receptor alpha expression: results from the soraya study
28. TP042/#1526 A single arm phase II study on pembrolizumab in pre-neoplastic high grade HPV-related vulvar and cervical lesions
29. TP030/#1426 EPIK-O/ENGOT-OV61: a phase 3, randomized study of alpelisib + olaparib in patients with no germline BRCA mutation detected, platinum-resistant or -refractory, high-grade serous ovarian cancer
30. EP264/#556 Physician-reported patient involvement in 1l ovarian cancer treatment, including maintenance, in the US and Europe: a real-world chart review analysis (2017–2020)
31. TP003/#1533 MITO CERV3_phase II study on carboplatin-paclitaxel-pembrolizumab in neoadjuvant treatment of locally advanced cervical cancer
32. 2022-RA-1540-ESGO MITO 25.1: a randomized, molecular driven phase II trial of carboplatin-paclitaxel-bevacizumab vs carboplatin-paclitaxel-bevacizumab-rucaparib vs carboplatin-paclitaxel-rucaparib, selected according to HRD status, in patients with advanced (Stage III B-C-IV) ovarian, primary peritoneal and fallopian tube cancer
33. 2022-RA-585-ESGO Come back to the future: the impact of estrogen receptor profile in the era of molecular endometrial cancer classification
34. 2022-RA-1623-ESGO Effect of bevacizumab and complete cytoreductive surgery in advanced low grade serous ovarian cancer: a secondary analysis of MITO 22
35. 2022-RA-1392-ESGO Tisotumab vedotin combinations with pembrolizumab or carboplatin in patients with recurrent/metastatic cervical cancer: interim results of ENGOT Cx8/GOG-3024/innovaTV205
36. 2022-LBA-746-ESGO Implementation of a comprehensive cancer genome profiling programme into clinical practice: an italian experience in a referral centre for gynecological cancers
37. 2022-RA-660-ESGO Characterization of extended treatment benefit from three phase 1 and 3 clinical trials examining patients with folate receptor alpha-positive recurrent ovarian cancer treated with single-agent mirvetuximab soravtansine
38. 2022-RA-1414-ESGO Pattern of recurrence and CA125 monitoring in BRCA wild-typerecurrent ovarian cancer patients under maintenance with Niraparib
39. 2022-RA-653-ESGO The impact of histology, prior therapy, and dMMR status on lenvatinib + pembrolizumab outcomes in patients with advanced endometrial cancer: A subgroup analysis of Study 309/KEYNOTE-775
40. 2022-LBA-677-ESGO Distribution and prognostic role of BRCA status in elderly ovarian cancer patients
41. 2022-RA-944-ESGO Real-world safety, baseline characteristics and first-year therapy management in patients withBRCA1/BRCA2-mutated advanced ovarian cancer treated with olaparib tablets in the first-line maintenance setting: first analysis of the pan-European OVAL-1 study
42. 2022-RA-1214-ESGO Best option treatment in first line setting for low grade serous ovarian cancer:a case-control study
43. 2022-RA-1294-ESGO Chemosensitivity in vulnerable older patients is unfavorable and highly dependent on the treatment regimen: CA125 elimination rate constant K (KELIM) analysis of the GINECO-ENGOT EWOC-1 trial
44. 2022-RA-1638-ESGO Randomized phase III trial on Niraparib-TSR-042 (dostarlimab) versus physician’s choice in recurrent ovarian, fallopian tube, or primary peritoneal cancer patients not candidate for platinum retreatment: NItCHE trial (MITO 33)
45. 2022-RA-249-ESGO Overall survival results from ariel3: a phase 3 randomised, double-blind study of rucaparib vs placebo following response to platinum-based chemotherapy for recurrent ovarian carcinoma
46. 366 Feasibility study of a network meta-analysis and unanchored population-adjusted indirect treatment comparison of niraparib, olaparib, and bevacizumab as maintenance therapies in patients with newly diagnosed advanced ovarian cancer
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.